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Abstract: Prevalence of allergy and allergic asthma are increasing worldwide. More than half 
of the US population has a positive skin prick test and approximately 10% are asthmatics. Many 
studies have been conducted to define immunological pathways underlying allergy and asthma 
development and to identify the main genetic determinants. In the effort to find missing pieces 
of the puzzle, new genomic approaches and more standardized ones, such as the candidate 
gene approach, have been used collectively. This article proposes an overview of the actual 
knowledge about immunological and genetic aspects of allergy and asthma. Special attention 
has been drawn to the challenges linked to genetic research in complex traits such as asthma 
and to the contribution of new genomic approaches.
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Allergy
Allergy, also called hypersensitivity, is a reaction that occurs when the immune  system 
responds to a harmless antigen.1 According to results published by the National Health 
and Nutrition Examination Surveys in 2005, more than half of the US population 
(54.3%) tests positive to one or more allergens (a common antigen that gives rise to 
an immediate hypersensitivity response)2 using skin prick tests between 1988 and 
1994.3 This survey also underlines the evidence of the growing prevalence of allergy 
in industrialized countries.
Allergies have been studied according to the different categories of allergens (indoor, 
outdoor, food, drug, etc) and according to the different allergic diseases (allergic rhinitis, 
atopic dermatitis, allergic asthma, etc). Prevalence of allergy to different types of antigen 
and prevalence of different allergic diseases ranges from 4% to 6% for food allergy,4 to 
10% for allergic asthma,5 and up to 49% reported in one study for allergic rhinitis.6
Immunology of allergy
Hypersensitivity reactions have been classified by Coombs and Gell into four  different 
types, characterized by different immunological mechanisms.7 These types have been 
well described in a review by Averbeck et al.1 A brief description of each type is as 
follows. Type I hypersensitivity refers to immediate hypersensitivity responses against 
foreign proteins that are common (pollen, grass, animal danders, etc). It can be observed 
in allergic rhinitis and allergic asthma (see section “immunology of asthma” for more 
detail).1,8 This type of hypersensitivity is characterized by immunoglobulin (Ig) E pro-
duction during the sensitization phase, which will bind to FcεRI receptors on mast cells 
and basophils. Upon renewed contact, the allergen will bind cellular IgE. Crosslinking 
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of FcεRI  receptors will lead to degranulation of mast cells and 
basophils (see Figure 1). Mediators released that way will lead 
to immediate and, sometimes, delayed immune responses.9,10
Type II hypersensitivity is a humoral response mediated by 
IgG or IgM that are produced against surface antigens on body 
cells. An example of type II hypersensitivity is drug-induced 
cytopenia caused by penicillin, cephalosporin, or transfusion 
reactions.1,11 Immune response occurs within minutes after 
antigen contact. In drug allergic subjects, IgG or IgM will 
be formed in response to drugs or their metabolites which 
accumulate in membrane structures. This binding will allow 
the killing of the target cells by three different ways.1,11 The 
first one is the activation of the classic complement pathway, 
which will lead to cytolysis. The second one is the antibody-
dependant cell-mediated cytotoxicity, which will lead to 
lysis of target cells by natural killer cells. The last one is the 
recognition of Fc fragments of IgG and IgM by phagocytic 
cells, which will lead to opsonization of the target cells.
Type III hypersensitivity involves the formation of immune 
complexes that are not well cleared by innate immune cells 
as in malaria, rheumatoid arthritis, or  farmer’s lung.1,12 This 
response can occur within four to six hours. The  accumulation 
of immune complexes (antigens bound to antibodies) in 
 vessels and tissues can be caused by antigen excess for 
subjects with immunosuppression or insufficient antibody 
production. It can also be caused by repeated antigen exposure 
which will lead to excess IgG antibody production. The pres-
ence of those persistent immune complexes will give rise to an 
inflammatory response due to leukocytes’ activation.1,12
Finally, type IV hypersensitivity is a delayed response 
principally mediated by T cells.1,13 The best known example 
of type IV hypersensitivity is contact allergy. The sensitization 
phase lasts 10–15 days and is asymptomatic. In contact allergy, 
a hapten, a low molecular weight molecule, will  interact with 
skin cells or proteins. After this contact, Langerhans and den-
dritic cells will present antigen to naive T cells to stimulate 
their differentiation into CD4+ and CD8+ T cells and to induce 
production of memory T cells. A renewed contact between the 
skin and the antigen will stimulate sensitized memory T cells 
via antigen-presenting cells. Early arrival of CD4+ and CD8+ 
T cells and activation of keratinocytes, will all contribute to 
promote inflammatory reaction via cytokine secretion. Finally, 
this reaction will be controlled by regulatory T cells.1,13
This classification of allergic reactions has been widely 
accepted but some revised nomenclature was proposed, such 
as that of Johansson et al14 who are part of the  European 
Academy of Allergy and Clinical Immunology. This revised 
nomenclature, based on known immune mechanisms of 
allergic diseases and hypersensitivity, aimed to classify 
the hypersensitivity reactions according to the presence of 
allergy, IgE production, and atopy. This classification gives 
a more universal definition of hypersensitivity, regardless of 
the targeted tissue or organ.
Genetics of allergy
Twin studies have demonstrated the strong heritable compo-
nent of allergic diseases and atopy, estimated at 33%–76%.15,16 
Twin studies with monozygous mice revealed that, even with 
the same controlled environment, phenotypic variability can 
Allergen
IgE
Mast cell
Degranulation
LTD4, PGD2, CCL19,
histamin, etc.
Figure 1 Mast cell activation after allergen contact.
Notes: when a first contact with allergen has already been made, immunoglobulin 
(ig) e against this allergen have been produced by B cells and have bound to FcεR1β 
receptors on mast cells. Another contact with the same allergen will allow its binding 
on cellular ige on mast cells. This will produce a crosslinking of FcεR1β, leading to 
activation and degranulation of mast cells within a few minutes. Modulators released 
by mast cells will promote inflammation by recruitment of new immune cells and 
activation of structural cells of the airways.
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occur in allergic manifestations. These results demonstrated 
that environment explains about 30% of the phenotypic 
variability observed in allergy and that 70% is due to other 
factors, such as epigenetics.17,18
However, search of the genes involved in allergy have 
been mostly done when studying genetic factors of allergic 
diseases (Table 1). Indeed, as mentioned by Hong et al,19 it 
is often difficult to evaluate the implication of genes on the 
development of allergy, using this method. However, Ren-
konen et al20 have recently published a review of the genetics 
of allergic diseases and have found 39 genes associated with 
allergy.20 In an effort to classify these genes according to 
their principal pathway, they concluded that 25 of them are 
involved in the same interaction pathway with another 70 
proteins. Among all of these proteins, 20 are linked to the 
“host–virus interactions”. When looking to Gene Ontology 
categories, “response to stress” and “response to various 
stimuli” were also significantly enriched.20 Another interest-
ing finding of this study is the proportion of protein kinases 
in their results (23%). Indeed, those kinases may be involved 
in active allergen transport through intact epithelium.20
To give a general idea of the genes identified by genetic 
studies on allergic diseases, here are some of the general 
pathways represented: the T helper type 2 (Th2) immune 
response and IgE switching cytokines and receptors (IL4RA, 
IL5, IL13, FCER1A, etc), the chemokines and chemokine 
receptors (CX3CR1, CCXCR1, CCR2, etc), the human leu-
kocyte antigen (HLA; HLA-DPB1, HLA-DQB1, etc), and 
the lipoxygenase and cyclooxygenase pathways (CYSLTR1, 
LTC4S, etc).6,19–26 Table 1 shows the prevalence of allergy or 
some of the most studied allergic diseases and the number 
of genes already associated with each ones.
Asthma
One of the most studied allergic diseases is asthma. Asthmatic 
response is provoked by allergy in 75%–80% of all asthmatic 
cases.29 According to the Global Initiative for Asthma,30 asthma 
is defined as a chronic inflammatory disorder of the airways 
involving many cells and mediators. The principal associated 
symptoms are airway hyperresponsiveness and usually reversible 
airflow obstruction. These symptoms lead to recurrent episodes 
of wheezing, breathlessness, chest tightness, and coughing.
Clinical manifestations of asthma often appear during 
childhood.31 However, some individuals show a late onset, 
sometimes after the age of 40 years.32 According to articles 
published between 1987 and 1997, the prevalence of asthma 
varied between 0.5% and 6% depending on the regions of the 
world.33–37 Approximately 10 years later, it is estimated that 
300 million people suffer from asthma in the world and 
that this number will reach 400 million people by 2025.5 
This  represent a world prevalence of approximately 10% 
and a prevalence of 14.1% for Canada and of 10.9% for the 
United States.5
Physiopathology and immunology 
of asthma
Asthma is a complex trait that is influenced by several genes as 
well as by the environment, thus it presents heterogeneous clini-
cal manifestations always recognized as different subphenotypes. 
Researchers agree that asthma is not a single disease but rather 
an array of disorders that share common characteristics.29,38,39 
These characteristics are inflammation, intermittent bronchial 
obstruction, bronchial hyperreactivity, mucus hypersecretion, 
and hypertrophy and hyperplasia of smooth muscle.8,38
As mentioned above, in 75%–80% of cases40,41 these 
phenotypes are caused by an allergic response, which 
 triggers a Th2 immune response.29 It is a type I hypersen-
sitivity reaction, that is an immediate exaggerated or harm-
ful immune reaction.8,42 Interestingly, only 7% of allergic 
people develop asthma,43 which can lead us to believe that 
they present a unique phenotype that distinguishes them 
from other allergic, but nonasthmatic, individuals. The main 
immune cells involved in asthma are CD4+ T cells, mast cells, 
and  eosinophils.44 The different steps of the inflammatory 
response in asthma, from contact with the allergen to remod-
eling, are illustrated in Figure 2 and explained later.
Contact with the allergen
When an allergen penetrates the airways, if not expulsed by 
the mucociliary barrier, it comes in contact with dendritic cells 
Table 1 Prevalence and number of genes associated with allergy 
or most studied allergic diseases27–29
Allergy/allergic  
disease
Prevalence Number of 
associated  
genes
References
Allergy 54% 43 3, 20, 27
Allergic asthma 10% More than 150 5, 22, 24 
Allergic rhinitis 9%–42% 21 6
Atopic  
dermatitis
16% of children  
in industrialized  
countries
46 21, 23
Drug allergy  
(aspirin  
intolerance)
1%–2% of all  
admissions and  
3%–5% of  
hospitalized patients
24 25, 26, 28
Food allergy 6% of children and  
up to 4% of adult
9 4, 19
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which will internalize and then digest the allergen. Some den-
dritic cells then migrate towards the lymph nodes to present the 
antigen to naive T cells (Figure 2A).45,46 This presentation hap-
pens through the major histocompatibility complex type II con-
jugated to the CD80 and CD86 costimulation molecules.47
The introduction of the antigen to naive T cells triggers 
the differentiation of CD4+ T cells into Th1 or Th2. This 
differentiation is modulated by the cytokines present dur-
ing the introduction of the allergen, eg, interleukin (IL)-12 
(Figure 2A).48 Evidence show, at least for mild to  moderate 
asthma, that Th2 cells predominate.49 Thus, after the dif-
ferentiation of naive T cells in Th2 cells, the latter produce 
cytokines, including IL-4 which induces the production of 
IgE by B lymphocytes (Figure 2A).
immediate response
When an individual has already been in contact with an aller-
gen, its presence and the presence of IgE can activate mast 
cells and stimulate their degranulation just minutes after the 
contact with the allergen.2,8 The activation happens when the 
allergen binds with more than one IgE, which are linked to 
their high-affinity receptor (FcεRI; Figure 2B).9,10 Mast cells 
are key cells in immediate response. In fact, mast cell granules 
contain proinflammatory molecules such as histamine, tryptase 
and other proteases, tumor necrosis  factor (TNF), and heparin.2 
New molecules are also produced and then released. These 
molecules are leukotrienes and prostaglandins, as well as 
cytokines, chemokines, and matrix metalloproteinases.2,50–53 The 
releasing of these mediators triggers the development of imme-
diate response symptoms such as coughing, bronchial spasms, 
smooth muscle contraction, oedema, mucus secretion, and infil-
tration of immune cells.8,54 Mast cells, through these mediators, 
contribute to the recruitment and activation of immune cells in 
the lungs, such as eosinophils, T cells, macrophages, basophils, 
neutrophils, structure cells (fibroblasts, smooth muscle and 
epithelial cells), and other mast cells.52,55,56
Basophils, with the presence of FcεRI receptors on their 
surface and the expression of Th2 cytokines, histamine 
and granules, can also play a role in immediate response. 
However, their role in asthma is less documented than that 
of mast cells.57
Delayed response
Delayed, or late response, is not present in all asthmatics. 
It is mainly modulated by immune cells recruited by mast 
cells (Figure 2C).8,29 Among these cells, eosinophils are the 
main cells implicated in the development of this response.58 
Eosinophils produce Th2 cytokines,59–61 leukotrienes,62–64 and 
proteins that cause damage to airway cells, such as major 
basic protein, eosinophil cationic protein, eosinophil-derived 
neurotoxin, and eosinophil peroxidase.65,66
Chronic inflammation in airways
Chronic response in asthma is characterized by a persisting 
inflammation and the presence of structure alterations in the 
airways (Figure 2D).67
Several immune cells play a role in this response. Mast 
cells participate in the chronic response through mediators 
that have an effect on bronchoconstriction and on airway 
remodeling causing contraction, hypertrophia and hyper-
plasia of smooth muscles as well as fibrogenesis.50–53,68,69 
Dendritic cells that remain in the airways after coming in 
contact with the allergen repeatedly present the antigen to 
CD4+ T cells.70 These cells, as well as the activated T cells, 
produce proinflammatory cytokines, maintain the chronicity 
of the inflammation and the eosinophilia.8,45,46,71 Eosinophils 
are indirectly involved in bronchial remodeling regarding 
collagen deposit, fibrogenesis, angiogenesis, and hyperplasia 
of smooth muscles in the peripheral airways via mediators 
secretion and other cells activation.58,72–74
Structural cells also play an important role in maintaining 
the chronic response. The amount of mucous epithelial cells 
increases in asthmatics, thus participating in the bronchial 
obstruction, mainly in peripheral airways.75,76 Furthermore, 
epithelial cells, smooth muscle cells, and fibroblasts produce 
and/or store cytokines, chemokines, and other proinflamma-
tory mediators.77–80 In asthmatics, fibroblasts also produce 
more collagen and other macromolecules for the extracel-
lular matrix, and present an increased differentiation in 
myofibroblasts.81,82
Phenotypic variability in asthma
To complete this overview of the asthmatic allergic response, 
the phenotypic heterogeneity has to be taken into consideration. 
Indeed, apart from allergic asthma, which is the most common 
form, other types of asthma have been described.8,38,83 One type 
is called nonallergic asthma, which develops  independently 
from an allergic component.32 More research still has to be 
conducted to better define biological pathways specific to 
this form of asthma.84,85 However, as with allergic asthma, the 
 scientific community recognizes that IgE could be implicated 
in an inflammatory cascade, as well as CD4+ and CD8+ T cells, 
eosinophils, and mast cells.86–91
A second type of asthma is characterized by sensitivity 
to aspirin. It is estimated that approximately 10%–20% of 
adult asthmatics suffer from this particular type.92 Aspirin 
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A
B
C
D
Epithelial cells
Hypersensitivity (permeability)
remodeling (metaplasia,
mucus secretion)
Fibroblast
Remodeling (collagen
and other macromolecules,
myofibroblast)
Smooth muscle cells
Bronchoconstriction
remodeling (hypertrophy
and hyperplasia)
Neutrophil
AM
Eosinophil
TGF-β, VEGF,
FGF, etc.
Mast cell
LTD4, PGD2, CCL19,
histamin, etc.
Basophil
IL-12
DC
IgE IgE
B
Allergen
T (naive)
IL-4
Th2
IL-5
IL-12
T (naive)
Th1
Figure 2 immune response in asthma.
Notes: The immune response in asthma begins with (A) the contact between 
antigen-presenting cells (mostly dendritic cells [DC]) and the allergen. These 
cells stimulate naive T cell differentiation into T helper type 1 (Th1) or Th2 
type. interleukin (iL)-4 secretion by Th2 cell leads to the immunoglobulin (ig) 
E production by B cells. IgE will bind to high-affinity receptors on mast cells and 
basophils and will allow immediate response to occur when another contact with 
the allergen will take place (B). After this new contact, mediators released by 
mast cells will induce recruitment and activation of other immune cell types as 
eosinophils, neutrophils, basophils, alveolar macrophages (AM), and structural cells 
(epithelial cells, smooth muscle cells, and fibroblasts). These cell types promote 
the delayed response that is not present in all asthmatic subjects (C). These cells 
not only promote the inflammatory response but also provoke hyperreactivity, 
bronchoconstriction, and remodeling. This will lead to asthma chronicity (D).
sensitization is thought to be non-IgE mediated so could be 
considered as a nonallergic subphenotype of asthma.92 A 
dysfunction of the eicosanoid metabolism is responsible for 
this type of asthma.92,93 A great number of individuals affected 
with this type of asthma will also resist a treatment with 
corticosteroids.38
Asthmatics who do not respond to glucocorticoid treat-
ments represent up to 10% of all patients affected with 
 asthma.94 This type of asthma can be induced by a diminution 
of the number of glucocorticoid receptors, by a misrecogni-
tion of the ligand by the receptors, by a decreased capacity 
of the receptors to link with DNA, or by an increase in the 
expression of certain proinflammatory transcription factors 
such as nuclear factor (NF)-κB.94
Occupational asthma is exacerbated or induced by irri-
tants or particles present in the workplace of the affected.95 It 
is estimated that 9%–15% of all cases of asthma in adults are 
linked to the workplace and that up to 25% of new cases of 
adult asthma fall in the occupational asthma category.96,97
Finally, exercise-induced asthma affects 7%–15% of 
the general population and 3%–14% of athletes.98 A study 
indicates that up to 39% of college athletes show one of the 
main symptoms of asthma, that is bronchoconstriction.99 
The two major hypotheses that could explain the induction 
of asthma after an effort are related to the augmentation of 
ventilation in the lungs.100,101 These two hypotheses are the 
osmotic hypothesis (dehydration by evaporation caused by 
the increase in ventilation) and the thermal hypothesis (airway 
cooling during exercise and rewarming after exercise).101–103 
According to Anderson and Daviskas,101 maybe a mix of these 
two hypotheses could better explain the phenotype rather 
than each one separately.
Asthma can also be classified according to inflamma-
tory patterns. The three principal types are eosinophilic 
asthma, neutrophilic asthma, and paucigranulocytic asthma.39 
Paucigranulocytic asthma is defined as an asthma response 
without eosinophils or neutrophils.29
Another way to classify asthma is according to the severity of 
the phenotype. This classification is used in the clinical treatment, 
but is also used in research in order to document the molecular 
and cellular biology variation related to the severity of the disease. 
Intermittent, mild, moderate, or severe asthma are part of this 
classification.104 The definition criteria of these types of asthma 
include frequency of day and night symptoms, exacerbation, and 
maximum expiratory flow in one second (Table 2).30
Changes in principal cells involved in the inflammatory 
response have been observed according to the severity of 
asthma. For example, inflammation is located in the main 
airways in individuals with mild asthma, whereas it is also 
present in peripheral airways and alveoli in individuals with 
severe asthma or during exacerbation.105 It is also interest-
ing to note that a recruitment of Th1 and CD8+ T cells 
(cytotoxic T cells) has also been observed in the case of 
severe and chronic asthma and during exacerbation.106–108 
Thus, other cell types involved in the Th1 response or in 
immune response regulation, such as alveolar macrophages 
(they inactivate dendritic cells and they can be activated or 
inhibited through different pathways),109–111 could play a role 
in the inflammatory response observed in asthma.112,113
Asthma genetics
Several studies demonstrated a strong familial structure in 
the prevalence of asthma.114–119 Studies conducted on twins on 
asthma and its subphenotypes (IgE, bronchial hyperreactivity, 
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etc) supported the idea of a genetic component in the devel-
opment of asthma.116 Segregation analyses subsequently 
demonstrated that asthma does not follow a Mendelian trans-
mission model. In fact, aggregation and segregation analyses 
have demonstrated that asthma is polygenic (several genes 
implicated), shows genetic heterogeneity (different combina-
tions of genes appear in the families that are studied), and 
pleiotropy (some genes are implicated in the development of 
more than one phenotype). Moreover, environment plays also 
a role in the development of the phenotype.116,120 According 
to this, asthma is considered as a complex trait.
Many challenges appear in genetic research on asthma, such 
as (1) finding all the genes associated with asthma and with 
treatment responses (build a list of asthma genes), (2) defin-
ing the mechanisms that trigger the phenotypic heterogeneity 
observed in asthma (assess the contribution of each gene in the 
different asthma phenotypes), (3) understanding the biology of 
the mutated genes in the  etiology of the disease (functional role 
of the associated genes), (4) understanding how the gene–gene 
and gene–environment interactions work (develop biological and 
mathematical analysis tools),121and (5) defining the impact of the 
epigenetic modulations on the development of asthma.120
The ultimate goal beyond these challenges is to define 
principal pathways involved in asthma and also  pathways 
specifically involved in asthma subphenotypes to find targets 
for new treatments.122 According to the great phenotypic 
variability observed in asthma, a more precise description of 
pathways involved in asthma subphenotypes would increase 
our chance to develop more efficient treatments for people 
who do not respond to actual therapy. An ideal therapy should 
be specific enough to be taken orally without affecting the 
immune response in the whole body.122 Actually, potential 
targets identified (for example, mediator antagonists and 
inhibitors of cytokines, p38 MAP kinase inhibitors, and anti-
inflammatory cytokines) are maybe too specific to be very 
effective.122 In the search for genes and pathways involved 
in asthma, association  studies between genes or the entire 
genome and drug response phenotypes could also lead to 
pharmacogenetic therapies.123 Indeed, characterizing the 
genetic profile of an asthmatic patient through genetic tests 
targeting specific genes of interest could help to select the 
appropriate treatment or to predict asthma development123,124 
and allow improved prevention programs.
Genes associated with asthma
Several reviews have described the knowledge acquired on 
the genetics of asthma.22,24,121,125 Figure 3 classified the main 
genes associated with asthma according to their biological 
function into three principal categories: inflammation, 
remodeling, and other pathways. Most of the associated 
genes could be classified into the inflammation (32/61; 
52%) or remodeling categories (12/61; 20%). Indeed, this 
classification not only underlines the great proportion of 
associated genes in the inflammatory response, but also 
underlines the need to better define the biological func-
tion for some of the other genes (other pathways; 17/61, 
28%) to better understand their implication in asthma. The 
complete list of genes for all categories seen in Figure 3 
is available in Table 3 with ontology keywords.
Table 4 presents the same 61 genes classified accord-
ing to the approach used to target them. As shown in this 
table, the main approach that has been used in the research 
of genetic determinants of asthma is the candidate gene 
approach. At the end of 2005, more than 100 genes had 
already been associated to asthma and another 54 associa-
tions have been performed in 2006 and 2007.22,24 Candidate 
gene association studies are based on the hypothesis of 
an association between the variants of a gene and asthma 
or one of its associated phenotypes. These phenotypes 
usually include respiratory capacity (wheezing, bronchial 
hyperreactivity, and pulmonary function measurements), 
immunological measures (total or specific blood IgE, 
allergy) or clinical criteria (atopic dermatitis, eczema, 
and rhinoconjunctivitis).121 This approach implies a lit-
erature review on genes involved in the development of 
the trait, or closely related to biological pathways linked 
with physiopathology of the trait. The choice of candidate 
genes can be based on several types of information: (1) 
gene functions, (2) documented associations with the trait 
in other populations or with closely related phenotypes, 
(3) difference of expression of the gene for the trait or a 
closely related phenotype, (4) at least one of these criteria 
documented for an animal model, or (5) association of 
another gene in the same biological pathway with the trait 
or with closely related phenotypes.22,127 Consequently, this 
approach is biased according to the literature already pub-
lished for the specific trait and the possibility of discovering 
new potentially interesting genes could be limited.22,127 This 
limitation may be even more important considering that the 
underlying biology of the development of most complex 
traits remains to be defined.127
In order to go past this candidate gene selection bias, sev-
eral approaches have been described. One of these is to select 
the candidate genes according to their known  functions and to 
crosscheck the results with data obtained from  genome-wide 
linkage, association, or expression studies.127 These genomic 
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approaches allow targeting of new genes without having to 
state a hypothesis regarding a specific gene or locus and, 
therefore, permit to increase the knowledge on the pathology 
of the trait.22,130
Before going further on the contributions of these 
techniques on the genetics of asthma, here is a brief descrip-
tion of each of them. Linkage analysis and genome-wide 
association studies (GWAS) are two techniques used to 
identify chromosomal loci associated in a studied trait. In 
both cases, analyses are based on two principles: equal 
transmission of alleles and increase in recombination for 
increased distances between two markers.131 To identify those 
loci, the linkage analysis uses families to compare microsat-
ellite markers transmission with phenotype transmission. 
Similarities between these two transmissions are translated 
into a statistical measure, the lod score. The lod score is 
greater when markers of a locus are more transmitted to sick 
children in studied families, and it is possible to hypothesize 
that genes near this locus are involved in the development 
of this disease.132 For GWAS, familial or case–control 
cohorts can be used.133 Contrary to linkage analysis, differ-
ent genetic variant types can be used for GWAS as coding 
single nucleotide polymorphisms (SNPs), tagging SNPs, 
or copy number variants. Figure 4 presents a brief descrip-
tion of the methodology used for this technique. Linkage 
analysis has been very efficient to target genes responsible 
of monogenic trait development but,132,134 in complex traits, 
one disadvantage of linkage analysis is its impossibility to 
detect locus with modest effect on phenotype compared 
with GWAS.22,135 GWAS also has the advantage of targeting 
more specific chromosomal regions (#500 bp) because of 
the great number of genetic variants (more than 500,000 
variants) represented on a microarray (for examples, see: 
http://www.illumina.com/).22 Moreover, new developments 
on genetics as HapMap international project, the development 
of new technologies as microarrays, and the possibility to 
bring together many samples owned by different researchers 
opened the way to GWAS.121,136
Genome-wide expression studies are another genomic 
approach that allow the identification of new genes and 
pathways involved in a target disease. Figure 4 presents the 
main technical steps to perform genome-wide expression 
studies using Affymetrix technology as example. These 
studies, as GWAS, used microarrays. The expression of 
more than 25,000 genes or transcripts can be measured in the 
same microarray (www.affymetrix.com). These are used to 
compare gene expression profiles of affected and nonaffected 
subjects, of treated and nontreated subjects, of measures for 
the same subjects at pretreatment and posttreatment, etc. 
Some advantages of genome-wide expression studies are 
accessibility of the microarray technology and analysis tools 
for researchers and clinicians, no sequencing step and possi-
bility to study thousands of genes simultaneously.137
About the contribution of these genome-wide techniques, 
the use of linkage studies has allowed targeting of genes 
involved in biological pathways that had not been studied in 
asthma before (Table 4). Several chromosomal regions have 
been associated with asthma using this method, but only a 
few have been replicated in several studies and populations 
(5q31–33, 6p21, 12q13–q24).22,138 GWAS and genome-wide 
expression studies are now also being used in order to target 
new genes or validate observations about already associated 
genes in asthma. Until now, more than 62 genome-wide 
expression studies have been performed on asthma or one 
of its subphenotypes (as found in PubMed using “asthma 
and microarray” and “asthma and gene chip” keywords and 
according to Rolph et al139). Although most results obtained 
from expression microarrays are exploratory and must be 
validated through functional or association studies, a few 
genes have been targeted by these analyses (Table 4).128 As for 
GWAS, only a few studies have been performed on asthma 
so far. The first was conducted during the summer of 2007 
Table 2 The definition criteria used to classify asthma according to severity
Severity Intermittent Mild persistent Moderate persistent Severe persistent
Symptom frequency Less than once a week More than once per week  
but less than once per day
Daily Daily
Nighttime symptoms Less than or equal to  
twice per month
More than twice per month More than once per week Frequent 
exacerbations Brief Could affect activities  
and sleep
Could affect activities and sleep Frequent 
Fev1 percent of  
predicted value
$80% $80% 60%–80% ,60%
variability of Fev1 ,20% 20%–30% .30% .30%
Note: Adapted from the Global Strategy for Asthma Management and Prevention, Global initiative for Asthma (GiNA).30
Abbreviation: Fev1, forced expiratory volume in the first second.
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and allowed targeting of a chromosomal region that regu-
lates the expression of the ORMDL3, GSDMB, and ZPBP2 
genes.140,141 However, GWAS approach is becoming more 
popular and many studies are underway in the field of asthma 
research. For example, to increase statistical power of the 
studies, researchers on asthma or other lung diseases group 
their samples together. Indeed, two major consortia have 
been made and will soon publish GWAS results. They are 
called GABRIEL Project (http://www.gabriel-fp6.org/) and 
EVE Asthma Genetics Consortium (http:// arrafunding.uchi-
cago.edu/investigators/ober_c.shtml). GABRIEL includes 
independent asthma genetics studies of European ancestry 
and EVE includes independent ones from the United States. 
The scientific community, including these two consortia and 
others, actually work to plane a meta-global GWAS analy-
sis. The great number of data researchers obtain from these 
studies will allow them to target new genes and pathways 
involved in asthma development or its subphenotypes. These 
may become new therapeutic candidates or may be part of a 
predictive genetic profile.124
Replication discrepancies
However, no matter what kind of approach is used, research-
ers are confronted with the same question: why is there an 
absence of validation in several cases? These nonreplications 
can be linked to the statistical power of the samples used, or 
to other phenotypic, genetic, environmental, or epigenetic 
concerns.121
To increase the chance to find polymorphisms associated 
with asthma and also replicate anterior results, statistical 
power of the sample is important. Genetic association studies 
are more powerful than genomic studies regarding number 
of subjects to number of genetic variants ratio. Indeed, with 
the great number of genetic variants or genes tested, the 
multiple testing problems are much more important in GWAS 
and genome-wide expression studies.142,143 It is known that 
for a GWAS, a sample of approximately 15,000 individuals 
would be necessary to obtain a statistical power of approxi-
mately 90% with a type I error of 5%.144 This objective can 
be reached by grouping together all asthma genetic research 
studies. For expression studies, analyses showed that at least 
three to five samples per phenotypic group could be sufficient 
to find a difference of expression, depending on the objective 
of the study (ie, to look at greater or smaller differences of 
expression).145
Another cause of replication discrepancies is the 
great phenotypic heterogeneity observed in asthma, 
as described in the section “Phenotypic variability in 
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Figure 3 Classification of the 61 main associated genes with asthma into biological functions.
Notes: This figure illustrates the two levels of classification of the 61 main associated genes with asthma. The first level of classification is made according to their known 
principal functions. From these known functions, a possible implication in the immune response or the remodeling response has been deduced. it is interesting to note that 
more than half (52%) of the main associated genes are in direct link with the immune response and that 20% may be involved in the remodeling process observed in asthma 
lung tissues. For the 17 genes classified in the “other pathways” category, their principal known function should help us orientate future research to better document their 
role in asthma. The complete list of genes for all categories seen in Figure 3 is available in Table 3 with ontology keywords.
Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
115
immunogenetics of asthma and allergy
Table 3 Classification of the 61 main genes associated with asthma according to their respective ontology keywords
Categories Gene symbol Gene ID Molecular functiona Biological processa
Inflammation
Cytokines and chemokines
CCL11 6356 Chemokine Cytokine and  
chemokine-mediated  
signaling pathway
CCL5 6352 Chemokine
CTLA4 1493 Other cytokine T-cell mediated immunity
IL18 3606 interleukin Cytokine and  
chemokine-mediated  
signaling pathway
IL4 3565 interleukin
IL13 3596 interleukin
IL10 3586 interleukin
IL4R 3566 interleukin receptor
LTA 4049 Tumor necrosis factor  
family member
SCGB1A1 (CC16) 7356 Other cytokine Other immune and defense
TNF 7124 Tumor necrosis factor  
family member
Cytokine and chemokine-mediated 
signaling pathway
Major histocompatibility complex
HLA-DRB1 3123 Major histocompatibility  
complex antigen
MHCii-mediated immunity
HLA-DQB1 3119 Major histocompatibility  
complex antigen
HLA-DPB1 3115 Major histocompatibility  
complex antigen
HLA-G 3135 Major histocompatibility  
complex antigen
Oxidative stress
GSTM1 2944 Other transferase Detoxification
GSTP1 2950 Other transferase
GSTT1 2952 Other transferase;  
epimerase/racemase
Receptors
CD14 929 Other receptor immunity and defense
CX3CR1 1524 G-protein coupled receptor Cytokine and chemokine-mediated 
signaling pathway
CYSLTR1 10800 G-protein coupled receptor immunity and defense
HAVCR1 26762 immunoglobulin receptor family  
member; defense/immunity protein
Other receptor-mediated  
signaling pathway
IRAK3 11213 Serine/threonine protein kinase  
receptor; protein kinase
Protein phosphorylation; other 
immune and defense
MS4A2 (FCER1B) 2206 immunoglobulin receptor family  
member; defense/immunity protein
B-cell mediated and antibody-mediated 
immunity; other  immune and defense
TRG@b T cell receptor gamma locus
Other pathways
ALOX15 246 Oxygenase Other lipid, fatty acid and steroid 
metabolism; immunity and defense
CMA1 1215 Serine protease Proteolysis; granulocyte-mediated 
immunity
HSPD1b 3329 Chaperonin Protein folding
LTC4S 4056  
 
Other transferase
Other lipid, fatty acid and  steroid 
metabolism; T-cell mediated immunity; 
B-cell mediated and antibody-6 + 
mediated immunity
PRNPb 5621 Molecular function unclassified Biological process unclassified
STAT6 6778 Other transcription factor;  
nucleic acid binding
mRNA transcription regulation;  
JAK-STAT cascade
TBX21 30009 Other transcription factor;  
nucleic acid binding
mRNA transcription regulation;  T-cell 
mediated immunity
(Continued)
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Table 3 (Continued)
Categories Gene symbol Gene ID Molecular functiona Biological processa
Remodeling
Growth factors and cell differentiation
AREG 374 Growth factor Ligand-mediated signaling
GSDMB 55876 Molecular function unclassified Developmental processes
TGFB1 7040 Growth factor Other receptor-mediated  signaling 
pathway
Proteolytic enzymes
ACE 1636 Metalloprotease Proteolysis
ADAM33 80332 Metalloprotease
CHI3L1 1116 Glycosidase Other polysaccharide metabolism
chi3l3 (ym1)b 12655  
(Mus musculus)
Molecular function unclassified Biological process unclassified
NOS1 4842 Synthase; oxidoreductase;  
calmodulin-related protein
electron transport
PLAU 5328 Serine protease Proteolysis
SERPINE1 (PAI1) 5054 Serine protease inhibitor
SERPINH1 871 Serine protease inhibitor
SERPINB4 6318 Serine protease inhibitor
Other pathways
Proteolytic enzymes
ARG1 383 Other hydrolase Amino acid catabolism
ARG2 384 Other hydrolase
NAT2 10 Acetyltransferase Other metabolism
PDE4D 5144 Phosphodiesterase Metabolism of cyclic nucleotides
Receptors
ADRB2 154 G-protein coupled receptor G-protein mediated signaling
NPSR1 (GPRA) 387129 G-protein coupled receptor
OPN3 23596 G-protein coupled receptor
TBXA2R 6915 G-protein coupled receptor G-protein mediated signaling
Structural proteins
FLG 2312 Other cytoskeletal proteins Protein complex assembly
Transcription factors
VDR 7421 Nuclear hormone receptor;  
transcription factor
mRNA transcription regulation
Others
COL29A1b 256076 Molecular function unclassified Cell adhesion
CYFIP2 26999 Other G-protein modulator Signal transduction
DPP10 57628 Select regulatory molecule Protein targeting and localization
ORMDL3 94103 Other miscellaneous function protein Miscellaneous
PHF11 51131 Double-stranded DNA binding protein General mRNA transcription activities
POSTN 10631 Other cell adhesion molecule Cell adhesion
SPINK5 11005 Select regulatory molecule Homeostasis
Notes: aOntology keywords from the Panther Classification System (http://www.pantherdb.org/). bGenes not recognized by the Panther Classification System. Those have 
been classified according to description available in Entrez Gene by NCBI (http://www.ncbi.nlm.nih.gov/gene). See also Madore et al.126
asthma”. This phenotypic heterogeneity can reflect geno-
typic heterogeneity, thus implying that the severity and 
onset of asthma could be influenced by the asthmatics’ 
genetic imprint.146,147 Thus, a precise characterization of 
the subjects remains essential. This precise phenotypic 
description of the sample helps to better select similar 
independent samples to replicate genetic association 
results and so helps to reduce the impact of differences 
in recruitment criteria and in population  stratification 
between samples.146 According to the fact that asthma 
is rather a collection of several diseases than a unique 
trait, the key of replication success may lie in association 
studies with asthma subphenotypes. The review article 
written by Wenzel39 presents several ways to categorize 
asthma subphenotypes that can be used for association 
and expression studies.
Gene–environment interactions are another source of 
variability since the environment can modulate the effect of 
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a gene on the resulting phenotype.148 Studies showed that 
gene–environment interactions had a greater effect on the 
phenotype than the environment and genes separately.149 For 
example, some studies have demonstrated that a high  exposure to 
endotoxin seems to switch the susceptibility effect of the CD14/-
159C allele to a protective effect compared with the CD14/-159T 
allele.150–152 Another example of gene–environment interaction is 
the interaction between polymorphisms in the regulating regions 
of a gene and the cell differentiation cycle, leading to differences 
on the expression of a specific allele.153
A part of the etiology of asthma could be explained by 
epigenetic changes. Epigenetics is the study of changes that 
are heritable and that modulate gene expression without 
directly altering gene sequence.120 Those changes can be done 
through DNA methylation or posttranslational modification 
of histones: eg, acetylation, methylation, phosphorylation, 
and ubiquitylation.154,155 Studies have demonstrated that 
epigenetic changes are heritable for almost two subsequent 
generations (eg, methylation of a coat-color gene in 
mice).156 Many studies in asthma underline the possible 
role of epigenetics in its development mostly for early onset 
asthma (for a review, see Miller and Ho120). For example, 
exposition to environmental tobacco smoke during prenatal 
development or during the first years of life could influence 
the development of asthma and may be transmitted across 
two generations.157–159
Gene–gene interactions are another source of  variability. 
In complex traits, a single mutation often has a minor 
impact, but the combination of several mutations should 
increase the influences on a phenotype. In asthma, a syn-
ergy between a mutation in the IL4 (rs2243250), the IL13 
(rs1800925), the IL4 R (rs1805010) and in the signal trans-
ducer and activator of  transcription 6 (STAT6) (rs324011) 
genes was documented and increases by 10.8 times the risk 
of having a high level of IgE and by 16.8 times the risk of 
developing asthma.160
The solution to these replication problems might partly 
lie in new genomic methods. In fact, new developments in 
the field of genetic and genomic research (for example, 
microarrays for GWAS and genome-wide expression 
studies), as well as knowledge acquired on the genome 
and its polymorphisms (as the HapMap project) allow the 
implementation of new analysis tools. Indeed, although 
there is still no consensus regarding the analysis methods 
that should be employed, new tools have been developed 
to overcome these problems. For example, many new 
software packages are developed or optimized regularly 
in Bioconductor, an open source software for the analysis 
Table 4 List of the 61 main associated genes in genetic and genomic studies on asthma and classified according to their identification 
method
Genes identification methods
Candidate genesa Linkage analysisb GWAS Genomic expression 
studyc
ADRB2 
ACE 
SCGB1A1 (CC16) 
CCL5 
CCL11 
CD14 
CMA1 
CTLA4 
MS4A2 (FCERIB) 
FLG 
GSTM1 
GSTP1 
GSTT1 
HAVCR1 
HLA-DPB1
HLA-DQB1 
HLA-DRB1 
IL4 
IL4R 
IL10 
IL13 
IL18 
LTA 
LTC4S 
NAT2 
NOS1 
SPINK5 
STAT6 
TBX21 
TBXA2R 
TGFB1 
TNF
ADAM33a 
COL29A1 
CYFIP2 
CYSLTR1 
DPP10 
HLA-G 
IRAKM 
NPSR1 (GPRA)a 
OPN3 
PHF11 
VDR
CHI3L1 
GSDMB 
ORMDL3 
PDE4D 
TCRγ ou  
TARP (BC072396)
ALOX15 
AREG 
ARGI 
ARGII 
CX3CR1 
HSPD1 
PLAU 
POSTN 
PRNP 
SERPINE1 (PAI-1) 
SERPINB4 
SERPINH1 
Yml (Chi3l3)
Abbreviation: GwAS, genome-wide association study.
Notes: aAssociated genes listed are those that have been replicated in almost five different studies according to Vercelli.121 Underlined genes are those that have been 
associated in more than 30 different studies.121 bAssociated genes are those targeted by linkage analysis according to Ober and Hoffjan22 and Moffatt.125 cPrincipal genes 
identified using genomic expression studies in asthma according to Izuhara and Saito.128 Genes in bold are those identified by Laprise et al129 and were positively associated 
with asthma. Genes in bold and underlined are those identified by Madore et al126 and that were validated by semi-quantitative real-time polymerase chain reaction (PCR). 
Double-underlined genes are newly five (or more) times associated genes in the 2009–2010 periods (keywords used in PubMed: gene association study).
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A
Genome-wide
amplification
Fragmentation
Fragmentation
Denaturation
Annealing on
microarrays
Annealing on
microarrays
Signal
amplification
(complementary
base and
antibody)
Analysis of
results
mRNA
Reverse
transcription
(cDNA)
In vitro
transcription
(cRNA)
Biotinylation
Analysis of
results
GWAS
(Illumina’s Infinium II)
B Genome-wide expression
(Affymetrix)
Figure 4 illustration of the methodological steps for genome-wide association 
studies and genome-wide expression studies.
Notes: Part A of this figure illustrates methodological steps of genome-wide 
association studies (GWAS) done using Illumina technology. Briefly, the first step 
is the amplification of the complete genome. Second, amplified DNA is fragmented 
using digestion enzymes. Denaturized fragments are then hybridized to short 
oligonucleotide sequences on microarrays. Finally, amplification with a fluorescent 
complementary base pair will allow reading and analyzing the results (illumina http://
www.illumina.com/pages.ilmn?iD=40). Part B of the figure illustrates methodological 
steps of genome-wide expression study performed using Affymetrix technology. 
The first step is the reverse transcription of mRNA into cDNA, followed by 
transcription of cDNA into cRNA. Afterward, cRNA is biotinylated, fragmented, 
and annealed with primers synthesized on the microarray. The signal intensity is 
proportional to the number of copies present in the sample.
and comprehension of genomic data, to better analyze 
and characterize data obtained from genome-wide studies 
(www.bioconductor.org). New genome-wide analysis tools 
are promising avenues to find new biological pathways, 
gene families or chromosomal loci involved in asthma and 
complex diseases, but candidate gene approach will remain 
a useful and powerful tool to refine our search for associ-
ated genes and to help better define the pathways involved 
in asthma development.
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